A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

• Status: Completed
• Trial end date: 2020-06-03
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal; Mirikizumab

Criteria

Inclusion Criteria:

• Participant must have chronic plaque psoriasis for at least 6 months.

Exclusion Criteria:

• Participant must not be breastfeeding or nursing woman.

• Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.

• Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.

• Participant must not have any other skin conditions (excluding psoriasis).

• Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).

• Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.

• Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).